AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

NCT02388295 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple System Atrophy, MSA

Interventions

DRUG: AZD3241
DRUG: Placebo

Sponsor

AstraZeneca